Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7859303 | 0.87 | ALDH1A1 (0.38) | GPR119HCRTR2HCRTR1 | |
| SCHEMBL10121579 | 0.86 | HCRTR1 (0.42) | HCRTR2HCRTR1HSD11B1 | |
| SCHEMBL10144795 | 0.83 | SYK (0.41) | GPR119HCRTR2HCRTR1SYK | |
| SCHEMBL611454 | 0.82 | GPR119 (0.37) | GPR119EIF2AK4 | |
| SCHEMBL609989 | 0.82 | GPR119 (0.36) | GPR119CETP | |
| SCHEMBL610838 | 0.81 | HCRTR1 (0.38) | GPR119HCRTR2HCRTR1 | |
| SCHEMBL609826 | 0.81 | HCRTR1 (0.38) | GPR119HCRTR2HCRTR1 | |
| SCHEMBL29913023 | 0.78 | JAK3 (0.41) | GPR119RORCHCRTR2TACR1SYK | |
| SCHEMBL606976 | 0.78 | HCRTR1 (0.49) | HCRTR2HCRTR1 | |
| SCHEMBL609058 | 0.77 | NR1H2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2010122151-A1 | 3 -AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CNR1 49/4885GPR119 17/4885RORC 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.